• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病的广泛认识。

Broad Views of Non-alcoholic Fatty Liver Disease.

机构信息

Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden; Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.

Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.

出版信息

Cell Syst. 2018 Jan 24;6(1):7-9. doi: 10.1016/j.cels.2018.01.004.

DOI:10.1016/j.cels.2018.01.004
PMID:29401451
Abstract

Multi-omics multi-tissue data are used to interpret genome-wide association study results from mice to identify key driver genes of non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat (steatosis) in the liver due to causes other than excessive alcohol consumption. The disease may progress to more severe forms of liver diseases, including non-alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. In this issue of Cell Systems, Krishnan et al. (2018) reveal mechanisms underlying NAFLD by generating multi-omics data using liver and adipose tissues obtained from the Hybrid Mouse Diversity Panel, consisting of 113 mouse strains with various degrees of NAFLD. The study identified key driver genes of NAFLD that can be used in the development of efficient treatment strategies and illustrates the potential utility of systematic analysis of multi-layer biological networks.

摘要

多组学多组织数据被用于解释来自小鼠的全基因组关联研究结果,以鉴定非酒精性脂肪性肝病的关键驱动基因。非酒精性脂肪性肝病(NAFLD)是由于除过量饮酒以外的原因导致肝脏脂肪(脂肪变性)堆积。该疾病可能进展为更严重的肝脏疾病,包括非酒精性脂肪性肝炎、肝硬化和肝细胞癌。在本期《Cell Systems》中,Krishnan 等人(2018 年)通过利用源自杂交小鼠多样性面板的肝脏和脂肪组织生成多组学数据,揭示了 NAFLD 的发生机制。该面板由 113 个具有不同程度 NAFLD 的小鼠品系组成。该研究鉴定了 NAFLD 的关键驱动基因,可用于开发有效的治疗策略,并说明了系统分析多层次生物网络的潜在效用。

相似文献

1
Broad Views of Non-alcoholic Fatty Liver Disease.非酒精性脂肪性肝病的广泛认识。
Cell Syst. 2018 Jan 24;6(1):7-9. doi: 10.1016/j.cels.2018.01.004.
2
Integration of Multi-omics Data from Mouse Diversity Panel Highlights Mitochondrial Dysfunction in Non-alcoholic Fatty Liver Disease.多组学数据整合揭示了小鼠多样性panel 中非酒精性脂肪性肝病中的线粒体功能障碍。
Cell Syst. 2018 Jan 24;6(1):103-115.e7. doi: 10.1016/j.cels.2017.12.006. Epub 2018 Jan 18.
3
Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease.非酒精性脂肪性肝病性别二态性的组织特异性途径和网络。
Biol Sex Differ. 2018 Oct 22;9(1):46. doi: 10.1186/s13293-018-0205-7.
4
System biology analysis reveals the role of voltage-dependent anion channel in mitochondrial dysfunction during non-alcoholic fatty liver disease progression into hepatocellular carcinoma.系统生物学分析揭示了电压依赖性阴离子通道在非酒精性脂肪性肝病进展为肝细胞癌过程中线粒体功能障碍中的作用。
Cancer Sci. 2020 Nov;111(11):4288-4302. doi: 10.1111/cas.14651. Epub 2020 Oct 6.
5
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.他汀类药物单独使用,或与吡格列酮及其他药物联合使用,用于治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎及相关心血管风险。专家小组声明。
Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4.
6
Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.高脂饮食诱导的非酒精性脂肪性肝病中外源物核受体的调控。
Toxicology. 2018 Dec 1;410:199-213. doi: 10.1016/j.tox.2018.08.007. Epub 2018 Aug 16.
7
Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.非酒精性脂肪性肝病的动物模型:当前观点与最新进展
J Pathol. 2017 Jan;241(1):36-44. doi: 10.1002/path.4829. Epub 2016 Nov 22.
8
MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.高脂饮食诱导的非酒精性脂肪性肝病-非酒精性脂肪性肝炎-肝细胞癌进展中的微小RNA表达分析:对C57BL/6J小鼠的研究
BMC Cancer. 2016 Jan 5;16:3. doi: 10.1186/s12885-015-2007-1.
9
Epigenetics in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中的表观遗传学。
Mol Aspects Med. 2017 Apr;54:78-88. doi: 10.1016/j.mam.2016.11.008. Epub 2016 Nov 23.
10
Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.在非酒精性脂肪性肝炎衍生的肝细胞癌小鼠模型中,降脂药物可抑制肝脂肪变性。
Eur J Pharmacol. 2016 Feb 5;772:22-32. doi: 10.1016/j.ejphar.2015.12.043. Epub 2015 Dec 24.

引用本文的文献

1
Genome-scale models in human metabologenomics.人类代谢组学中的基因组规模模型
Nat Rev Genet. 2025 Feb;26(2):123-140. doi: 10.1038/s41576-024-00768-0. Epub 2024 Sep 19.
2
Multiple reaction monitoring assays for large-scale quantitation of proteins from 20 mouse organs and tissues.用于从 20 种鼠器官和组织中大规模定量蛋白质的多重反应监测分析。
Commun Biol. 2024 Jan 2;7(1):6. doi: 10.1038/s42003-023-05687-0.
3
Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase.鞣花酸及其代谢物作为肝丙酮酸激酶的有效和选择性别构抑制剂。
Nutrients. 2023 Jan 22;15(3):577. doi: 10.3390/nu15030577.
4
Genetic polymorphisms of gene and their associations with milk production traits in Chinese Holstein cows.中国荷斯坦奶牛基因的遗传多态性及其与产奶性状的关联
Front Genet. 2022 Sep 2;13:1002706. doi: 10.3389/fgene.2022.1002706. eCollection 2022.
5
Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet.联合代谢激活剂通过激活高脂饮食喂养仓鼠的线粒体代谢来减轻肝脏脂肪变性。
Biomedicines. 2021 Oct 11;9(10):1440. doi: 10.3390/biomedicines9101440.
6
Found in translation-core network preservation across liver diseases and species.在跨肝脏疾病和物种的翻译核心网络中发现。
Cell Rep Med. 2021 Jul 21;2(7):100347. doi: 10.1016/j.xcrm.2021.100347. eCollection 2021 Jul 20.
7
Hepatic transcriptome and DNA methylation patterns following perinatal and chronic BPS exposure in male mice.围产期和慢性 BPS 暴露后雄性小鼠的肝转录组和 DNA 甲基化模式。
BMC Genomics. 2020 Dec 9;21(1):881. doi: 10.1186/s12864-020-07294-3.
8
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.载脂蛋白 C-III 在人类富含甘油三酯脂蛋白代谢中的作用。
Front Endocrinol (Lausanne). 2020 Jul 28;11:474. doi: 10.3389/fendo.2020.00474. eCollection 2020.
9
The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease.代谢辅因子补充的急性作用:一种针对非酒精性脂肪性肝病的潜在治疗策略。
Mol Syst Biol. 2020 Apr;16(4):e9495. doi: 10.15252/msb.209495.
10
Inhibition of Heme Oxygenase Antioxidant Activity Exacerbates Hepatic Steatosis and Fibrosis .抑制血红素加氧酶抗氧化活性会加剧肝脏脂肪变性和纤维化。
Antioxidants (Basel). 2019 Aug 5;8(8):277. doi: 10.3390/antiox8080277.